Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study

Javier Martínez-Sanz; Alfonso Muriel; Raquel Ron; Sabina Herrera; José A. Pérez-Molina; Santiago Moreno; Sergio Serrano-Villar

doi:10.1101/2020.06.08.20125245

Article Information

doi

https://doi.org/10.1101/2020.06.08.20125245

History

June 9, 2020.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

Javier Martínez-Sanz1,
Alfonso Muriel2,
Raquel Ron1,
Sabina Herrera1,
José A. Pérez-Molina1,
Santiago Moreno1,*,† and
Sergio Serrano-Villar1,*,†

¹Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain
²Clinical Biostatistic Unit, Hospital Universitario Ramón y Cajal, Departamento de Enfermería y Fisioterapia, Universidad de Alcalá, IRYCIS, CIBERESP, Madrid, Spain

↵†Correspondence to: Javier Martínez-Sanz, MD, PhD. Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá (IRYCIS). Carretera de Colmenar Viejo, Km 9.100, 28034 Madrid, Spain. Tel: +34 913 368 975; E-mail: javier.martinez.sanz{at}salud.madrid.org., Sergio Serrano-Villar, MD, PhD. Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá (IRYCIS). Carretera de Colmenar Viejo, Km 9.100, 28034 Madrid, Spain. Tel: +34 913 368 975; E-mail: sergio.serrano{at}salud.madrid.org.